Herantis Pharma Oyj has decided to focus a significant majority of the company's development efforts to advance HER-096, a small molecule synthetic peptidomimetic of Cerebral Dopaminergic Neurotrophic Factor or CDNF. HER-096 combines the compelling mode of action of CDNF protein to target Parkinson's disease with the ease of subcutaneous administration. The company expects filing for regulatory approval in Fourth Quarter 2022 to start a first-in-man clinical study of HER-096.